ClinicalTrials.gg

Program

vonaprument

Also written as “ANX007”, “Vonaprument” and “2.5mg ANX007”.

Its studies are mostly in Geographic Atrophy · Glaucoma, Open-Angle, led by Annexon.

Furthest: phase 3, since Jul 15, 20245 company-led studies, 2 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Annexon52 open or runningphase 3since Jul 15, 2024Mar 28, 2018Jul 31, 2027phase 3 · NCT06510816

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2018First study: phase 1 study in Glaucoma, Open-AngleFirst studyNCT03488550 · 9 enrolled · United States
  2. Dec 13, 2018Phase 1 study in Glaucoma, Open-AngleNCT04188015 · 17 enrolled · United States
  3. Dec 1, 2020Phase 2 study in Geographic AtrophyNCT04656561 · 270 enrolled · United States, Australia, New Zealand
  4. Jul 15, 2024Phase 3 study in Geographic AtrophyNCT06510816 · 659 enrolled · United States, Australia, Austria and more
  5. Sep 3, 2026Phase 3 study in Geographic AtrophyNCT07807969 · 605 planned · United States

Ahead

  1. Jul 31, 2027Primary completion: phase 3 study in Geographic AtrophyNCT06510816
  2. Jul 31, 2029Primary completion: phase 3 study in Geographic AtrophyNCT07807969

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07807969Geographic Atrophy · United States3Not yet recruitingJul 31, 2029605
NCT06510816Geographic Atrophy · United States, Australia, Austria and more3Active, not recruitingJul 31, 2027659
NCT04656561Geographic Atrophy · United States, Australia, New Zealand2CompletedMar 28, 2023270
NCT04188015Glaucoma, Open-Angle · United States1CompletedJun 3, 201917
NCT03488550Glaucoma, Open-Angle · United States1CompletedAug 3, 20189

How it is read

Names in the registry

  • “ANX007”, 2 entries
  • “Vonaprument”, 2 entries
  • “2.5mg ANX007”, 1 entry
  • “5.0mg ANX007”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.